Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorde la Fuente Vivas, Dalia
dc.contributor.authorCAPPITELLI, VINCENZO
dc.contributor.authorGarcía Gómez, Rocío
dc.contributor.authorValero Díaz, Sara
dc.contributor.authorAmato, Camilla
dc.contributor.authorRodriguez, Javier
dc.contributor.authorDuro Sánchez, Santiago
dc.contributor.authorArribas, Joaquin
dc.date.accessioned2025-03-06T13:36:19Z
dc.date.available2025-03-06T13:36:19Z
dc.date.copyright2024
dc.date.issued2025-02
dc.identifier.citationde la Fuente-Vivas D, Cappitelli V, García-Gómez R, Valero-Díaz S, Amato C, Rodriguéz J, et al. ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility. Mol Oncol. 2025 Feb;19(2):452-73.
dc.identifier.issn1878-0261
dc.identifier.urihttp://hdl.handle.net/11351/12701
dc.descriptionMAP kinases; Cell motility; Scaffold proteins
dc.description.abstractERK1/2 mitogen-activated protein kinases (ERK) are key regulators of basic cellular processes, including proliferation, survival, and migration. Upon phosphorylation, ERK becomes activated and a portion of it dimerizes. The importance of ERK activation in specific cellular events is generally well documented, but the role played by dimerization is largely unknown. Here, we demonstrate that impeding ERK dimerization precludes cellular movement by interfering with the molecular machinery that executes the rearrangements of the actin cytoskeleton. We also show that a constitutively dimeric ERK mutant can drive cell motility per se, demonstrating that ERK dimerization is both necessary and sufficient for inducing cellular migration. Importantly, we unveil that the scaffold protein kinase suppressor of Ras 1 (KSR1) is a critical element for endowing external agonists, acting through tyrosine kinase receptors, with the capacity to induce ERK dimerization and, subsequently, to unleash cellular motion. In agreement, clinical data disclose that high KSR1 expression levels correlate with greater metastatic potential and adverse evolution of mammary tumors. Overall, our results portray both ERK dimerization and KSR1 as essential factors for the regulation of cell motility and mammary tumor dissemination.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesMolecular Oncology;19(2)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMama - Càncer - Aspectes genètics
dc.subjectCèl·lules - Motilitat
dc.subjectProteïnes quinases activades per mitògens
dc.subject.meshBreast Neoplasms
dc.subject.mesh/genetics
dc.subject.meshMitogen-Activated Protein Kinase 1
dc.subject.meshCell Movement
dc.titleERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/1878-0261.13732
dc.subject.decsneoplasias de la mama
dc.subject.decs/genética
dc.subject.decsproteína cinasa activada por mitógenos 1
dc.subject.decsmovimiento celular
dc.relation.publishversionhttps://doi.org/10.1002/1878-0261.13732
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[de la Fuente-Vivas D, Cappitelli V, Valero-Díaz S, Amato C] Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) – Universidad de Cantabria, Santander, Spain. [García-Gómez R] Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) – Universidad de Cantabria, Santander, Spain. Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain. [Rodriguéz J] Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, UK. [Duro-Sánchez S, Arribas J] Centro de Investigacion Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain. Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain. Preclinical and Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid39263917
dc.identifier.wos001310564500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record